Small-Cell Lung Cancer Drug Market Will More Than Double to Over $684 Million in 2017
... of Genentech/Roche/Chugai's Avastin and Celgene's amrubicin
(currently marketed in Japan as Calsed by Nippon K...s a first-line add-on to standard chemotherapy and amrubicin
as a second-line therapy will drive robust 22 perc...ore, despite the impressive sales that Avastin and amrubicin
will add to the market, these therapies will have ...
Amrubicin Shows Encouraging Results for Small Cell Lung Cancer Treatment
...n terms of response rate and safety when comparing amrubicin
to the current treatment standard, topotecan, in s...mall cell lung cancer."
The trial compares amrubicin
and topotecan in patients with ED-SCLC that initia... participants are randomized 2:1 to receive either amrubicin
(40 mg/m2 via 5- min.infusion daily x 3 days) or t...
Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
Interim analysis of Phase 2 clinical data presented at the 2007 Chemotherapy Foundation Symposium
BOULDER, Colo., Nov. 9 /PRNewswire-FirstCall/ -- Pharmion Corporation
(Nasdaq: PHRM ) today released interim findings from its Phase 2 trial of
Amrubicin in second-line chem...
Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
BOULDER, Colo., Oct. 17 /PRNewswire-FirstCall/ -- Pharmion Corporation
(Nasdaq: PHRM ) today announced the initiation of an international pivotal
Phase 3 clinical trial evaluating amrubicin, the Company's third-generation
synthetic anthracycline, in the treatment of second-line small cell lun...
Pharmion's Amrubicin Shows Encouraging Results Compared to Standard
of Care in Second Line Treatment of Small Cell Lung Cancer
Interim Analysis of Phase 2 Clinical Data Published at the American
Society of Clinical Oncology 43rd Annual Meeting
CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Pharmion
Corporation today released interim findings from its Phase II,
multi-center clinical study of Amrubicin, the company's
Pharmion to Present Clinical Data on Commercial and Pipeline
Products at 2007 American Society of Clinical Oncology (ASCO)
Interim data on a Phase II study of amrubicin
appears in the
ASCO 2007 conference publication, a... June 4,
2007; 11:00-11:15am; Arie Crown Theater
A randomized phase II trial of amrubicin
vs. Topotecan as
second-line treatment in extensiv...